A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 15100 participants.

Also called NCT07000357

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 15,100 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07000357
  • EudraCT 2025-520519-14
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark, France, Germany, Greece, Hungary, India, Italy, Japan, Malaysia, Mexico, New Zealand, Peru, Philippines, Poland, Puerto Rico, Romania, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07000357. Randomized; quadruple masking; primary purpose treatment. Start 2025-06-04 (actual); primary completion 2029-10-26 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Acronym
AZURE-Outcomes
Condition
Cardiovascular Disease
Intervention (Drug)
AZD0780
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07000357
Content hash
7975b34a912c972437fbc74c49a01a8688abb8dc49e4d8d3d29f8d2bc5e2c3de